| Field | Specification |
|---|---|
| Organism | |
| Applications | |
| Tissue | |
| Disease | Prostate carcinoma |
| Sex | |
| Growth properties | |
| Biosafety level | |
| Product format | Frozen |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Overview
Ace-1 cells were derived from a dog with spontaneous prostate cancer. Ace-1 cells metastasize primarily to the appendicular and axial skeleton after injection into the left cardiac ventricle in mice.
Key elements and design rationale
- Model identity: Ace-1 Cells (Luciferase Transduced) is supplied as a tumor cell line derived from Dog prostate.
- Growth properties: Adherent, epithelial
- Growth conditions: PriCoat™ ECM T25 Flasks (G999) or Applied Cell Extracellular Matrix (G422) are required for cell adhesion to the culture vessels. PriGrow IV (TM004) + 10% FBS (*Regular) + 1% Penicillin/Streptomycin Solution (G255), 37.0°C, 5% CO₂. *Do not heat-inactivate
- Engineering / immortalization: Luciferase reporter expression.
- Product format: Frozen, BSL-2
This cell-based model is generally used in vascular biology, signaling, and assay development studies. Donor/background information is available for contextual interpretation.
Biological background
Ace-1 cells can be xenografted to immunosuppressed laboratory beagles. The Ace-1 cell line demonstrates marked epithelial-mesenchymal transition and produces mixed osteoblastic and osteolytic metastases. Cells have been transduced with a luciferase reporter which allows for monitoring of tumor growth using bioluminescent imaging. The Ace-1 cells can be used to develop an experimental model of prostate cancer in immunosuppressed dogs to investigate molecular imaging, focal therapy of prostate cancer, and metastasis to lymph nodes, lungs and bone. Donor/background information provided for this product: Male, Prostate carcinoma.
Research relevance and current trends
- Cell-line models continue to be used for tumor phenotype comparison, pathway perturbation studies, and assay development in controlled in vitro systems.
- Engineered and subtype-defined tumor lines are often used to compare growth behavior, reporter output, and response patterns across matched experimental conditions.
- When metastatic or lineage features are described, investigators commonly interpret results alongside morphology, passage history, and culture environment.
Common research applications
- Cancer biology studies that compare proliferation-associated behavior, morphology, and pathway responses in vitro.
- Assay development for treatment response, reporter monitoring, or phenotype comparison under matched culture conditions.
- Side-by-side comparison of engineered versus parental background characteristics when relevant to the study design.
Changes in morphology, growth rate, viability, or reporter signal are typically interpreted together with passage history, culture matrix, and the specified growth conditions for the model.
Notes for experimental interpretation
- Morphology, doubling behavior, and reporter or marker output can shift with passage number, substrate choice, and medium composition; these variables should be recorded alongside experimental readouts.
- Matched controls such as parental cells, untreated cultures, or parallel cultures maintained under identical conditions help distinguish background effects from biology of interest.
Culture and product details
- Growth Conditions: PriCoat™ ECM T25 Flasks (G999) or Applied Cell Extracellular Matrix (G422) are required for cell adhesion to the culture vessels. PriGrow IV (TM004) + 10% FBS (*Regular) + 1% Penicillin/Streptomycin Solution (G255), 37.0°C, 5% CO₂. *Do not heat-inactivate
- Seeding Density (cells/cm²): 10,000
—
🧊 Thawing Protocol
- Thaw cells quickly in a 37°C water bath while agitating gently (maximum 2 minutes). The vial cap should be kept above the water level to minimize the risk of contamination.
- Decontaminate the vial by spraying and wiping the exterior of the vial with 70% ethanol. From this point onwards, all operations should be strictly carried out inside a biological safety cabinet using aseptic conditions.
- Transfer the cell suspension into a 15ml sterile conical tube containing 5ml of pre-warmed, complete growth media. Centrifuge cells at 125xg for 5-7 minutes.
- Aspirate the supernatant without disturbing the cell pellet. Re-suspend the cell pellet in the recommended pre-warmed, complete growth media and dispense into a T25 culture flask.
- Incubate the cells at the recommended conditions.
🔬 Subculture Protocol
Volumes given below are for a T75 flask; proportionally increase or decrease the volume as required per culture vessel size. Subculture cells once the culture vessel is 80% confluent.
- Aspirate the culture media, and add 2-3ml of pre-warmed 0.25% Trypsin-EDTA to the culture vessel.
- Observe the cells under a microscope to confirm detachment (typically within 2-10 minutes). Cells that are difficult to detach can be put in 37°C, for several minutes to facilitate detachment.
- Neutralize Trypsin-EDTA by adding an equal volume of the complete growth media into the culture vessel.
- Transfer the culture suspension into a sterile centrifuge tube, and centrifuge at 125xg for 5 minutes. The actual centrifuge duration and speed may vary depending on the cell type.
- Aspirate the supernatant, and re-suspend the pellet with pre-warmed fresh complete growth media. Add appropriate aliquots of the cell suspension to new culture vessels, as desired.
- Incubate the cells at the recommended conditions.
How should I handle live cells once I receive them?
Please refer to our Cell Handling and Thawing Guidelines for detailed instructions on receiving, thawing, and culturing live cells:
https://www.abmgood.com/immortalized-cells-documents.html
Following these guidelines will help ensure optimal cell viability and performance.
https://www.abmgood.com/immortalized-cells-documents.html
Following these guidelines will help ensure optimal cell viability and performance.
Why are these cells classified as biosafety level II?
We follow the CDC-NIH recommendations that all mammalian sourced products should be handled at the Biological Safety Level 2 to minimize exposure of potentially infectious products. This information can be found in 'Biosafety in Microbiological and Biomedical Laboratories' (1999). Your institution's Safety Officer or Technical Services will be able to make the call as to whether BioSafety Level I is possible with these cells at your site, if desired.
What is your warranty or return policy?
Our warranty and return policy is outlined in abm’s Terms and Conditions, including details on product quality, limitations, and claims.
Please refer to the following link for full information:
https://www.abmgood.com/terms
For additional questions, our Order team is happy to assist and can be reached at order@abmgood.com.
Please refer to the following link for full information:
https://www.abmgood.com/terms
For additional questions, our Order team is happy to assist and can be reached at order@abmgood.com.
How many times can cells divide?
The number of times cells can divide depends on the cell type:
Primary cells have a limited lifespan and will undergo a finite number of population doublings before entering senescence. The exact number varies by cell type and culture conditions.
Immortalized cell lines are capable of extended or indefinite proliferation under proper culture conditions, although growth characteristics may vary between lines.
Primary cells have a limited lifespan and will undergo a finite number of population doublings before entering senescence. The exact number varies by cell type and culture conditions.
Immortalized cell lines are capable of extended or indefinite proliferation under proper culture conditions, although growth characteristics may vary between lines.
Do I need Applied Cell Extracellular Matrix (G422) if I am using PriCoat™ flasks?
Please refer to the Growth Conditions section of your specific product page. This section will indicate whether Applied Cell Extracellular Matrix (G422), PriCoat™ flasks, or both are recommended for optimal cell attachment and growth, as requirements may vary by cell type.
Cell line sourcing and selection (species, tissue, and disease model matching) · Stable cell line engineering (overexpression, knockdown, knockout via CRISPR/Cas9, shRNA, sgRNA) · Reporter gene integration (GFP, RFP, luciferase, fluorescent/bioluminescent constructs) · Genome editing and knockin (point mutations, tagged endogenous proteins, conditional alleles) · Inducible expression systems (Tet-On/Off and regulatable constructs) · Drug resistance marker selection (puromycin, G418, hygromycin, and others) · Custom growth and media optimisation for specific assay requirements · Scale-up production for high-throughput screening campaigns · Authentication and QC services (STR profiling, mycoplasma testing, viability assessment). Talk to a Scientist or contact support@biohippo.com.
Halvorson, K. G., Kubota, K., Sevcik, M. A., Lindsay, T. H., Sotillo, J. E., Ghilardi, J. R., Rosol, T. J., Boustany, L., Shelton, D. L., & Mantyh, P. W. (2005). A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer research, 65(20), 9426–9435. https://doi.org/10.1158/0008-5472.CAN-05-0826
Halvorson, K. G., Sevcik, M. A., Ghilardi, J. R., Rosol, T. J., & Mantyh, P. W. (2006). Similarities and differences in tumor growth, skeletal remodeling and pain in an osteolytic and osteoblastic model of bone cancer. The Clinical journal of pain, 22(7), 587–600. https://doi.org/10.1097/01.ajp.0000210902.67849.e6
LeRoy, B. E., Thudi, N. K., Nadella, M. V., Toribio, R. E., Tannehill-Gregg, S. H., van Bokhoven, A., Davis, D., Corn, S., & Rosol, T. J. (2006). New bone formation and osteolysis by a metastatic, highly invasive canine prostate carcinoma xenograft. The Prostate, 66(11), 1213–1222. https://doi.org/10.1002/pros.20408
Alvarez, F. J., Murahari, S., Couto, C. G., Rosol, T. J., Kulp, S. K., Chen, C. S., & Kisseberth, W. C. (2007). 3-Phosphoinositide-dependent protein kinase-1/Akt signalling and inhibition in a canine prostate carcinoma cell line. Veterinary and comparative oncology, 5(1), 47–58. https://doi.org/10.1111/j.1476-5829.2006.00117.x
Thudi, N. K., Martin, C. K., Nadella, M. V., Fernandez, S. A., Werbeck, J. L., Pinzone, J. J., & Rosol, T. J. (2008). Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions. The Prostate, 68(10), 1116–1125. https://doi.org/10.1002/pros.20776
Jimenez-Andrade, J. M., Bloom, A. P., Stake, J. I., Mantyh, W. G., Taylor, R. N., Freeman, K. T., Ghilardi, J. R., Kuskowski, M. A., & Mantyh, P. W. (2010). Pathological sprouting of adult nociceptors in chronic prostate cancer-induced bone pain. The Journal of neuroscience : the official journal of the Society for Neuroscience, 30(44), 14649–14656. https://doi.org/10.1523/JNEUROSCI.3300-10.2010
Jimenez-Andrade, J. M., Bloom, A. P., Stake, J. I., Mantyh, W. G., Taylor, R. N., Freeman, K. T., Ghilardi, J. R., Kuskowski, M. A., & Mantyh, P. W. (2010). Pathological sprouting of adult nociceptors in chronic prostate cancer-induced bone pain. The Journal of neuroscience : the official journal of the Society for Neuroscience, 30(44), 14649–14656. https://doi.org/10.1523/JNEUROSCI.3300-10.2010
Jimenez-Andrade, J. M., Ghilardi, J. R., Castañeda-Corral, G., Kuskowski, M. A., & Mantyh, P. W. (2011). Preventive or late administration of anti-NGF therapy attenuates tumor-induced nerve sprouting, neuroma formation, and cancer pain. Pain, 152(11), 2564–2574. https://doi.org/10.1016/j.pain.2011.07.020
Li, X., Liao, J., Park, S. I., Koh, A. J., Sadler, W. D., Pienta, K. J., Rosol, T. J., & McCauley, L. K. (2011). Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone. Bone, 48(6), 1354–1361. https://doi.org/10.1016/j.bone.2011.03.687
Stokol, T., Daddona, J. L., Mubayed, L. S., Trimpert, J., & Kang, S. (2011). Evaluation of tissue factor expression in canine tumor cells. American journal of veterinary research, 72(8), 1097–1106. https://doi.org/10.2460/ajvr.72.8.1097
Thudi, N. K., Martin, C. K., Murahari, S., Shu, S. T., Lanigan, L. G., Werbeck, J. L., Keller, E. T., McCauley, L. K., Pinzone, J. J., & Rosol, T. J. (2011). Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases. The Prostate, 71(6), 615–625. https://doi.org/10.1002/pros.21277
Hojjat, S. P., Foltz, W., Wise-Milestone, L., & Whyne, C. M. (2012). Multimodal μCT/μMR based semiautomated segmentation of rat vertebrae affected by mixed osteolytic/osteoblastic metastases. Medical physics, 39(5), 2848–2853. https://doi.org/10.1118/1.3703590
Park, S. I., & McCauley, L. K. (2012). Nuclear localization of parathyroid hormone-related peptide confers resistance to anoikis in prostate cancer cells. Endocrine-related cancer, 19(3), 243–254. https://doi.org/10.1530/ERC-11-0278
Schade, G. R., Keller, J., Ives, K., Cheng, X., Rosol, T. J., Keller, E., & Roberts, W. W. (2012). Histotripsy focal ablation of implanted prostate tumor in an ACE-1 canine cancer model. The Journal of urology, 188(5), 1957–1964. https://doi.org/10.1016/j.juro.2012.07.006
Senapati, S., Chakraborty, S., Nath, I., K Panda, S., C Patra, R., & K Batra, S. (2012). Non-human prostate cancer cell lines. Oncology, Gastroenterology and Hepatology Reports, 1(1), 15–24. doi:10.5530/ogh.2012.1.5
10%
OFF
20%
OFF
$50
OFF
FREE
SAMPLE
